The goal of this study is to determine if either of two, commercially available, Echinacea purpurea products stimulate the immune system. For the study, 60 healthy adults will be randomized to receive one of the two Echinacea purpurea products or placebo for 10 days. Blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. It is postulated that adults receiving either of the Echinacea products will have evidence of immune stimulation and those receiving placebo will not.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
67
5 ml by mouth 3 times per day for 10 days
1 ml by mouth 3 times per day for 10 days
either 5 ml or 1 ml by mouth three times per day for 10 days
Bastyr University
Kenmore, Washington, United States
Peak Level of TNF Alpha
Highest level of TNF alpha while taking study medication
Time frame: 1-10 days after starting study medication
Peak Level IL-6
Highest level of IL-6 while taking study medication
Time frame: 1-10 days after starting study medication
Peak Level Interferon Gamma
Highest level of Interferon gamma while taking study medication
Time frame: 1-10 days after starting study medication
Peak Level IL-2
Highest level of IL-2 while taking study medication
Time frame: 1-10 days after starting study medication
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Adverse events such as nausea or rash in participants receiving an Echinacea formulation or placebo will be compared
Time frame: 1- 30 days after starting study medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.